{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:40:06Z","timestamp":1749948006273,"version":"3.41.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Cytomegalovirus (CMV) infection following allogeneic hematopoietic cell transplantation has considerable morbidity and mortality, and foscarnet is a treatment option that requires renal dose adjustment. Serum creatinine (SCr)-based estimated glomerular filtration rate (eGFR) equations are used to estimate renal function for patients receiving foscarnet, but cystatin C (cysC) has been shown as a possible alternative. Data examining cysC-based eGFR in this population is sparse. Our primary objective was to evaluate outcomes of patients treated with foscarnet dosed utilizing cysC-based eGFR versus SCr-based eGFR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We analyzed patients on the transplantation and cellular therapies service at Memorial Sloan Kettering Kids from January 2011 to September 2021 who received allogeneic hematopoietic cell transplantation and \u226514 days of foscarnet for CMV infection. Patients with cysC-based eGFR were compared to a historical cohort of patients who only had SCr-based eGFR. Outcomes included time to CMV clearance, death or change in anti-CMV therapy. Cumulative incidence curves and cause-specific hazards model were used for analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In 61 analyzed patients, no differences were found between the cohorts in cumulative incidence of change in anti-CMV therapy (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.17) or death (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.69). After adjustment for multiple confounders, patients in the SCr cohort seemed to have a higher chance of CMV clearance compared with the cysC cohort, but the difference was not statistically significant (hazard ratio = 2.42, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.089). Patients who received corticosteroids appeared to have lower incidence of CMV clearance (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.056).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>We did not find differences in outcomes when dosing foscarnet using cysC versus SCr for treatment of CMV infection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004238","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T22:00:09Z","timestamp":1704751209000},"page":"457-462","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective Evaluation of Cystatin C as a Measure of Renal Function in Pediatric Hematopoietic Stem Cell Transplant Patients Receiving Foscarnet for Cytomegalovirus Reactivation"],"prefix":"10.1097","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-7776","authenticated-orcid":false,"given":"Logan R.","family":"Pickett","sequence":"first","affiliation":[{"name":"From the Department of Pharmacy, Children\u2019s Healthcare of Atlanta, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole P.","family":"Daukshus","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York City, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Camacho-Bydume","sequence":"additional","affiliation":[{"name":"Department of Pediatric Blood and Marrow Transplant and Cellular Therapy, Joseph M. Sanzari Children\u2019s Hospital, Hackensack University Medical Center, Hackensack, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York City, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York City, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cancio","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York City, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States.","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00277-019-03755-2","article-title":"Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study.","volume":"98","author":"Czy\u017cewski","year":"2019","journal-title":"Ann Hematol"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jmii.2015.07.011","article-title":"Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients.","volume":"50","author":"Wu","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.bbmt.2016.04.004","article-title":"Cytomegalovirus infection in pediatric hematopoietic stem cell transplantation: risk factors for primary infection and cases of recurrent and late infection at a single center.","volume":"22","author":"Rowe","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R5-20250614","first-page":"6551","article-title":"Risk factors for cytomegalovirus infection after allogeneic hematopoietic cell transplantation in malignancies: proposal for classification.","volume":"37","author":"Dziedzic","year":"2017","journal-title":"Anticancer Res"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MPH.0000000000000730","article-title":"Cytomegalovirus treatment in pediatric hematopoietic stem cell transplant patients.","volume":"39","author":"Wattles","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","article-title":"Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation.","volume":"7","author":"Styczynski","year":"2018","journal-title":"Infect Dis Ther"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/pharmacy8010035","article-title":"Cystatin C: a primer for pharmacists.","volume":"8","author":"Teaford","year":"2020","journal-title":"Pharmacy (Basel)"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C.","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/phar.2175","article-title":"Impact of serum cystatin C-based glomerular filtration rate estimates on drug dose selection in hospitalized patients.","volume":"38","author":"Peters","year":"2018","journal-title":"Pharmacotherapy"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1214234","article-title":"Cystatin C versus creatinine in determining risk based on kidney function.","volume":"369","author":"Shlipak","year":"2013","journal-title":"N Engl J Med"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00467-012-2341-3","article-title":"Performance of cystatin C-based equations in a pediatric cohort at high risk of kidney injury.","volume":"28","author":"Nehus","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/MNM.0b013e328334fc6f","article-title":"Can serum cystatin C reflect the glomerular filtration rate accurately in pediatric patients under chemotherapeutic treatment? A comparative study with Tc-99m DTPA two-plasma sample method.","volume":"31","author":"Aydin","year":"2010","journal-title":"Nucl Med Commun"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.ki.5002231","article-title":"Modified RIFLE criteria in critically ill children with acute kidney injury.","volume":"71","author":"Akcan-Arikan","year":"2007","journal-title":"Kidney Int"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/ki.2012.169","article-title":"Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C.","volume":"82","author":"Schwartz","year":"2012","journal-title":"Kidney Int"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.ajkd.2011.05.019","article-title":"Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values.","volume":"58","author":"Inker","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1681\/ASN.2010050483","article-title":"Cystatin C identifies chronic kidney disease patients at higher risk for complications.","volume":"22","author":"Peralta","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.ajkd.2007.11.018","article-title":"Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.","volume":"51","author":"Stevens","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents.","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/s41409-018-0428-6","article-title":"A novel strategy for identifying early acute kidney injury in pediatric hematopoietic stem cell transplantation.","volume":"54","author":"Benoit","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.bbmt.2012.06.006","article-title":"Cystatin C-estimated glomerular filtration rate in pediatric autologous hematopoietic stem cell transplantation.","volume":"18","author":"Laskin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.bbmt.2014.07.008","article-title":"Estimated versus measured glomerular filtration rate in children before hematopoietic cell transplantation.","volume":"20","author":"Laskin","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.kint.2020.10.047","article-title":"Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease.","volume":"99","author":"Pierce","year":"2021","journal-title":"Kidney Int"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:49Z","timestamp":1749945649000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004238","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}